Mechanisms of resistance to daptomycin in Enterococcus faecium

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 3, 2008, Pages 1167-1170

  Montera, Clemente I ^a,b   Stock, Frida ^a   Murray, Patrick R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Clinical Center Building 10   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLONING; ENTEROCOCCUS FAECIUM; LEUKOCYTE ADHERENCE; LEUKOCYTE ADHESION DEFICIENCY; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SOIL MICROFLORA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DAPTOMYCIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LEUKOCYTE-ADHESION DEFICIENCY SYNDROME; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; POLYMERASE CHAIN REACTION; VANCOMYCIN;

EID: 40549095283     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00774-07     Document Type: Article

References (26)

1. Boucher, H. W., and G. Sakoulas. 2007. Perspectives on daptomycin resistance, with emphasis on resistance in aureus. Clin. Infect. Dis. 45:601-608.
2. Carpenter, C. F., and H. F. Chambers. 2004. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. 38:994-1000.
3. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement M100-216, vol. 26. CLSI, Wayne, PA.
4. Cui, L. Z., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
5. D'Costa, V. M., K. M. McGrann, D. W. Hughes, and G. D. Wright. 2006. Sampling the antibiotic resistome. Science 311:374-377.
6. Debono, M., B. J. Abbott, R. M. Molloy, D. S. Fukuda, A. H. Hunt, V. M. Daupert, F. T. Counter, J. L. Ott, C. B. Carrell, L. C. Howard, et al. 1988. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J. Antibiot. (Tokyo) 41:1093-1105. (In Japanese.)
7. Depardieu, F., B. Perichon, and P. Courvalin. 2004. Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR. J. Clin. Microbiol. 42:5857-5860.
8. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
9. Friedman, L., J. D. Alder, and J. A. Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145.
10. Greenberg, D. E., L. Ding, A. M. Zelazny, F. Stock, A. Wong, V. L. Anderson, G. Miller, D. E. Kleiner, A. R. Tenorio, L. Brinster, D. W. Dorward, P. R. Murray, and S. M. Holland. 2006. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PloS Pathog. 2:260-267.
11. Handwerger, S., and J. Skoble. 1995. Identification of chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 39:2446-2453.
12. Harrington, S. M., F. Stock, A. L. Kominsky, J. D. Campbell, J. C. Hormzabal, S. Livio, L. Rao, K. L. Kotloff, S. O. Sow, and P. R. Murray. 2007. Genotypic analysis of invasive Streptococcus pneumoniae from Mali, Africa, by semi-automated repetitive-element PCR and pulsed-field gel electrophoresis. J. Clin. Microbiol. 45:707-714.
13. Hayden, M. K., K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn, and R. A. Weinstein. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
14. Jung, D., A. Rozek, M. Okon, and R. E. Hancock. 2004. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 11:949-957.
15. Lewis, J. S., 2nd, A. Owens, J. Cadena, K. Sabol, J. E. Patterson, and J. H. Jorgensen. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 49:1664-1665.
16. Mangili, A., I. Bica, D. R. Snydman, and D. H. Hamer. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060.
17. Miranda, A. G., K. V. Singh, and B. E. Murray. 1991. DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool. J. Clin. Microbiol. 29:2752-2757.
18. Munoz-Price, L. S., K. Lolans, and J. P. Quinn. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin. Infect. Dis. 41:565-566.
19. Patel, J. B., L. A. Jevitt, J. Hageman, L. C. McDonald, and F. C. Tenover. 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42:1652-1653.
20. Pfaller, M. A., H. S. Sader, and R. N. Jones. 2007. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn. Microbiol. Infect. Dis. 57:459-465.
21. Pillai, S. K., H. S. Gold, G. Sakoulas, C. Wennersten, R. C. Moellering, and G. M. Eliopoulos. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob. Agents Chemother. 51:2223-2225.
22. Sader, H. S., J. M. Streit, T. R. Fritsche, and R. N. Jones. 2006. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin. Microbiol. Infect. 12:844-852.
23. Sakoulas, G., J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
24. Shepard, B. D., and M. S. Gilmore. 2002. Antibiotic-resistant enterococci: the mechanisms and dynamics of drug introduction and resistance. Microbes Infect. 4:215-224.
25. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
26. Vouillamoz, J., P. Moreillon, M. Giddey, and J. M. Entenza. 2006. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J. Antimicrob. Chemother. 58:1208-1214.